@therabeneinc

Founded in 2020. We develops highly targeted PROTAC molecules to attack cancers. We envisioning a better outcomes for patiens and their families

Publication

AI-Integrated QSAR Modeling for Enhanced Drug Discovery: From Classical Approaches to Deep Learning and Structural Insight
AI-Integrated QSAR Modeling for Enhanced Drug Discovery: From Classical Approaches to Deep Learning and Structural Insight
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders
Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders

News

The upcoming AACR-NCI-EORTC International Conference (October 22–26, 2025) 
The upcoming AACR-NCI-EORTC International Conference (October 22–26, 2025) 
Therabene Inc. presented AI-driven degrader therapeutics at Massachusetts Life Sciences Center (MLSC) and looks forward to expanding this partnership. 
Therabene Inc. presented AI-driven degrader therapeutics at Massachusetts Life Sciences Center (MLSC) and looks forward to expanding this partnership. 
Therabene Inc. Press Release 2: Therabene Inc. Appoints Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development
Therabene Inc. Press Release 2: Therabene Inc. Appoints Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development
Therabene Inc. Announces Positive Preclinical Results for Two Promising New Molecules in Collaboration with Biocytogen
Therabene Inc. Announces Positive Preclinical Results for Two Promising New Molecules in Collaboration with Biocytogen
Therabene Inc. Press Release 1: Therabene Inc. Announces Positive Preclinical Results for Two Promising New Molecules in Collaboration with Biocytogen
Therabene Inc. Press Release 1: Therabene Inc. Announces Positive Preclinical Results for Two Promising New Molecules in Collaboration with Biocytogen
Mario DiPaola, PhD, MBA - Top Execs
Mario DiPaola, PhD, MBA - Top Execs
Mario DiPaola: Creating Legacy in Biotechnology and Pharmaceuticals | Co-Founder and CEO at Therebene, Inc
Mario DiPaola: Creating Legacy in Biotechnology and Pharmaceuticals | Co-Founder and CEO at Therebene, Inc

View on mobile